Canada · Delayed Price · Currency is CAD Rubicon Organics Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 revenue grew 23% year-over-year, driven by higher yields and initial Cascadia output. Gross margin improved to 36% (excluding pre-revenue costs), with automation and international expansion supporting future growth. Premium market share and brand strength remain high.
-
Premium cannabis brands are driving growth through consistent quality, proprietary genetics, and operational expansion, with a major revenue inflection expected from the new Cascadia facility in H2 2026. International sales are rising, especially in the UK, and margins are set to improve.
-
Q1 2026 saw 11% revenue growth year-over-year, despite margin pressure from Cascadia ramp-up and BC strike impacts. Premium market share increased, with strong brand performance and international expansion underway. Margin and revenue inflection expected in H2 2026.
Fiscal Year 2025
-
Record 2025 results included 22% revenue and 25% Adjusted EBITDA growth, driven by premium brand strength and the operational launch of the Cascadia facility, which expanded capacity by 40%. Margin improvement and further growth are expected in 2026 as Cascadia ramps up and new market opportunities are pursued.
-
Record Q3 revenue grew 16% year-over-year, with strong brand performance and positive cash flow. Cascadia facility launch increases capacity by 40%, though short-term margin pressure is expected as it ramps up. Premium market share and international expansion continue to drive growth.
-
Record Q2 2025 results with $15M net revenue (up 24% YoY), $5.9M gross profit, and $1.4M adjusted EBITDA. Expansion with Hope facility boosts capacity by 40%, while strong growth in vapes and pre-rolls drives outperformance.
-
The meeting confirmed all procedural requirements, elected eight directors, and reappointed the auditor. Financial results showed strong revenue growth and profitability, with strategic expansion through the Hope, BC facility and continued focus on premium brands and international markets.
-
Q1 2025 saw 39% revenue growth and positive adjusted EBITDA, driven by premium brands and new product launches. Expansion with the Hope facility will boost capacity by 40%, with no revenue expected until 2026, while the company maintains strong liquidity and targets further growth in both domestic and international markets.
-
Global cannabis supply shortages and rising international demand are fueling growth, with strong financial performance, award-winning brands, and expanded production capacity positioning for further gains. New product launches and international expansion are key 2025–2026 priorities.
-
Canadian cannabis leaders showcased operational excellence, innovation, and strong financials, with strategies focused on premium products, loyalty programs, and international expansion. Companies are scaling efficiently, investing in automation, and leveraging brand strength to capture market share and drive profitability.
Fiscal Year 2024
-
Record net revenue and profitability were achieved in 2024, driven by strong brand performance, successful vape launches, and disciplined financial management. Expansion with the Hope facility and international shipments set the stage for further growth, with 2025 guidance forecasting continued revenue and EBITDA gains.
-
Record Q3 net revenue and gross margin recovery were driven by strong premium market share and a successful vape launch, with vapes expected to contribute over 20% growth on 2023 revenue by 2025. The company is expanding capacity, preparing for international entry, and progressing toward debt refinancing.
-
A leading Canadian premium cannabis producer highlighted its organic focus, strong brand portfolio, and disciplined financial management, achieving two years of profitability. Growth is driven by new product launches, contract manufacturing, and rising international demand, with a strategic shift toward brand power and CPG-style operations.
-
Record Q2 net revenue and positive adjusted EBITDA were driven by strong premium market share and successful new product launches, especially in vapes and edibles. Cash flow and margins improved, with continued growth and profitability expected for 2024.
-
The meeting confirmed quorum, elected eight directors, reappointed the auditor, and approved a new equity plan. Two years of Adjusted EBITDA profitability were highlighted, with strategic growth focused on premium brands, new product launches, and national expansion.